STAT1d
There is no ‘amyloid cabal’ in Alzheimer’s research
There exists no ‘amyloid cabal’” in Alzheimer’s research, neurologist Dennis Selkoe writes in response to Charles Piller’s ...
Nasdaq19d
FDA approves IV maintenance dosing of Leqembi® (lecanemab-irmb) for the treatment of early Alzheimer's Disease in the US
Data from the off-treatment period between the Phase 2 core study and its long-term extension (LTE) showed that discontinuation of treatment is associated with reaccumulation of brain amyloid ...
Nasdaq29d
Intellia Loses 21.6% in a Week: How Should You Play the Stock?
Nexiguran ziclumeran is being studied for two indications — ATTR amyloidosis with polyneuropathy (ATTRv-PN) and ATTR amyloidosis with cardiomyopathy (ATTR-CM). The phase III MAGNITUDE study is ...